Predicting the immunity landscape and prognosis with an NCLs signature in liver hepatocellular carcinoma.

Zhangxin JiChenxu ZhangJingjing YuanQing HeXinyu ZhangDongmei YangNa XuJun Chu

Published in: PloS one (2024)

Overall, we have developed a prognostic signature that can discriminate different LIHC subgroups through the 5 selected NCLs, with the objective of providing LIHC patients a more precise, personalized treatment regimen.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
patient reported outcomes
smoking cessation